Xenbase Image ID: 79188

Fig. 7. Effects of Xror2 and its mutant constructs on morphogenetic movements of animal caps stimulated with activin. Two-cell stage embryos were injected with mRNAs of globin (A,F), Xror2 (B,G), Xror2-3I (C), Xror2-TM (D,I), Xror2-KR (E) or a mixture of Xror2 and Xror2-TM (H) in the animal pole region of both blastomeres. Doses of injected mRNA (ng/embryo) are indicated in parentheses. Note that doses of mRNA used in F-I are lower than in A-E. Animal caps (stages 8-8.5) were treated with (right panels in A-E; F-I) or without (left panels in A-E) activin A as indicated and cultured until sibling stage 18. A-E and F-I are separate experiments. Activin treatment initiated elongation of control animal caps (A,F). Xror2 (B), Xror2-3I (C) and Xror2-TM (D) suppressed elongation of animal caps by activin. In Xror2-TM-expressing animal caps, a neural groove-like structure with pigmented cells (black arrowheads) was observed in activin-treated ones. Elongation of Xror2-KR-expressing animal caps treated with activin was slightly reduced (E), compared with globin-expressing animal caps. Xror2 or Xror2-TM with lower doses show moderate inhibition of activin-induced elongation of animal caps (G,I). Co-expression of Xror2 and Xror2-TM shows cumulative effects on the inhibition of activin-induced elongation, indicating that wild-type and Xror2-TM do not compete with each other (H). Image published in: Hikasa H et al. (2002) Copyright © 2002. Image reproduced with permission of the publisher and the copyright holder. This is an Open Access article distributed under the terms of the Creative Commons Attribution License. Larger Image Printer Friendly View

Return to previous page